<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01453257</url>
  </required_header>
  <id_info>
    <org_study_id>C62 202-878</org_study_id>
    <nct_id>NCT01453257</nct_id>
  </id_info>
  <brief_title>Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients</brief_title>
  <acronym>TT</acronym>
  <official_title>A Phase 2 Study of Target-Guided Personalized Chemotherapy in Metastatic Colorectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Hospital de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Hospital de Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment options for patients with colorectal cancer (CRC) have increased in the last years.
      However, there are no validated prospective molecular markers in CRC to select which agents
      are better to treat any individual case. The conventional first-line treatment in CRC
      patients in clinical studies get a proportion of patients free of progression at 12 months
      ranging from 35-40% with a median of 9 months of free disease progression.

      The aim of this study is to demonstrate that the identification of therapeutic targets in
      real time and their prospectively use to customize the treatment get a proportion of
      colorectal metastatic patients patients free of progression disease at 12 months of 50%.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Progression Free Survival</condition>
  <arm_group>
    <arm_group_label>Chemotherapy treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tailored chemotherapy by Therapeutic Targets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tailored Chemotherapy</intervention_name>
    <description>Patients will be treated with Folfox, Folfiri, Xelox or Xeliri and Cetuximab or Bevacizumab at usual doses tailored by:
K-ras native: Cetuximab. K-ras mutated: Bevacizumab Topoisomera 1 positive ( Topo-1): Irinotecan Topo-1 positive and ERCC-1 negative: oxaliplatin Topo-1 1 negative and ERCC-1 positive: investigator option Thimidylate synthase (TS) positive: No Fluoropyrimidines (FLP) TS negative: FLP Thimidylate phosphorylasa (TP) positive: Capecitabine TP negative: 5-FU</description>
    <arm_group_label>Chemotherapy treatment</arm_group_label>
    <other_name>Biomarker selection</other_name>
    <other_name>Therapeutic Targets chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Colorectal adenocarcinoma stage IV patients.

          -  ECOG= 0-1

          -  Age &gt; 18 years.

          -  Fit to receive chemotherapy treatment

          -  Availability of tumor tissue or possibility of a tumor biopsy to determine therapeutic
             targets.

          -  Adequate renal (Cr &lt; 1,5 mg/d), liver (bilirubin≤1,5 mg/dl, AST and ALT ≤ 3.0 x the
             upper limit of normal) and normal bone marrow function ( absolute neutrophil count ≥
             1500/µl, hemoglobin ≥ 9.0g/dl and a platelet count of ≥ 100.000/µl)

        Exclusion Criteria:

          -  Contraindication for the administration of any of the drugs used in the study
             including capecitabine, irinotecan, oxaliplatin, cetuximab or bevacizumab.

          -  Previous Chemotherapy treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Cubillo, Md PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo Hospital madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Integral Oncológico Clara campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2011</study_first_submitted>
  <study_first_submitted_qc>October 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2011</study_first_posted>
  <last_update_submitted>October 18, 2011</last_update_submitted>
  <last_update_submitted_qc>October 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Grupo Hospital de Madrid</investigator_affiliation>
    <investigator_full_name>Sofia Perea, PharmD, PhD</investigator_full_name>
    <investigator_title>Fundación Hospital de mADRID</investigator_title>
  </responsible_party>
  <keyword>Molecular Targets</keyword>
  <keyword>Personalize Treatment</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>Complete Response Rate</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

